IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
ARROWHEAD PHARMACEUTICALS, INC. vs LANCASTER COLONY CORP — Side-by-side quantitative comparison
Based on our 6-factor quantitative model, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is the stronger stock with a composite score of 67.3/100 and a Buy rating, compared to LANCASTER COLONY CORP (MZTI) at 58.0/100 (Hold). ARWR ranks #186 in our universe versus #892 for MZTI, giving it an edge of 9.3 points across quality, value, momentum, investment, stability, and short interest factors.
For the Quality factor — which measures profitability and business quality through metrics like ROE, gross margins, and capital efficiency — ARWR leads at 89/100, while MZTI trails at 71/100 (ARWR: 89/100, MZTI: 71/100). The 17-point gap indicates a meaningful difference in quality characteristics between these stocks.
For the Value factor — which evaluates whether a stock is cheap or expensive relative to its earnings, book value, and cash flows — ARWR leads at 77/100, while MZTI trails at 69/100 (ARWR: 77/100, MZTI: 69/100). The 8-point gap indicates a meaningful difference in value characteristics between these stocks.
For the Momentum factor — which captures price trends and institutional sentiment over the trailing 3-12 months — ARWR leads at 92/100, while MZTI trails at 36/100 (ARWR: 92/100, MZTI: 36/100). The 56-point gap indicates a meaningful difference in momentum characteristics between these stocks.
For the Investment factor — which assesses capital allocation quality including reinvestment rates and asset growth — MZTI leads at 39/100, while ARWR trails at 27/100 (MZTI: 39/100, ARWR: 27/100). The 13-point gap indicates a meaningful difference in investment characteristics between these stocks.
For the Stability factor — which measures financial health through leverage ratios and price volatility — MZTI leads at 88/100, while ARWR trails at 45/100 (MZTI: 88/100, ARWR: 45/100). The 43-point gap indicates a meaningful difference in stability characteristics between these stocks.
For the Short Interest factor — which tracks institutional bearish positioning and potential risk from elevated short selling — MZTI leads at 58/100, while ARWR trails at 32/100 (MZTI: 58/100, ARWR: 32/100). The 25-point gap indicates a meaningful difference in short interest characteristics between these stocks.
Based on our 6-factor model, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is utilizing a stronger overall profile than MZTI, with a Composite Score of 67 vs 58. ARWR holds a moderate edge, particularly in Momentum and Quality, though both stocks have merits.
| Overall Rating | ||
| Composite Score | 67 | 58 |
| Rank | #186 | #892 |
| Stars | 4 / 5 | 3 / 5 |
| Action | Buy | Hold |
| Factor Scores | ||
| Quality | 89 | 71 |
| Value | 77 | 69 |
| Momentum | 92 | 36 |
| Stability | 45 | 88 |
| Investment | 27 | 39 |
| Short Interest | 32 | 58 |
| Valuation | ||
| P/E Ratio | — | 25.21 |
| P/B Ratio | 4.18 | 4.67 |
| P/S Ratio | 19.65 | 2.41 |
| EV/EBITDA | — | 15.35 |
| Dividend Yield | 0.0% | 2.2% |
| Profitability | ||
| ROE | 8.7% | 18.5% |
| ROA | 2.4% | 14.5% |
| Gross Margin | 100.0% | 24.1% |
| Operating Margin | 11.9% | 12.0% |
| Net Margin | 3.6% | 9.6% |
| Growth & Risk | ||
| Revenue Growth | 23258.2% | 5.8% |
| Debt/Equity | 55.00 | 0.00 |
| Beta | 1.67 | 0.25 |
| Market | ||
| Market Cap | $4.77B | $4.76B |
Based on our 6-factor quantitative model, ARWR currently has the higher composite score (67.3/100, Buy) and ranks #186 in our universe. However, the "better" stock depends on your investment goals, risk tolerance, and time horizon. We recommend reviewing the full factor breakdown above before making a decision.
Our comparison analyzes six quantitative factors: Quality (profitability and business strength, 30% weight), Momentum (price trends, 25%), Value (valuation attractiveness, 15%), Investment (capital allocation, 10%), Stability (financial health, 10%), and Short Interest (institutional positioning, 10%). Each factor is scored 0-100 and combined into a composite score.
ARWR has the higher value score at 77/100 compared to MZTI at 69/100. A higher value score indicates the stock trades at a more attractive valuation relative to its earnings, book value, and cash flows.
Our stock rankings and comparisons are updated daily using the latest available market data, financial statements, and price information. Factor scores reflect the most recent quarterly filings and trailing price data.